Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2018
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of adults with previously treated advanced renal cell carcinoma
19 September 2018 - Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus ...
Posted by Michael Wonder on 15 Sep 2018
Herceptin (trastuzumab) subcutaneous formulation approved in Canada for the treatment of HER2-positive breast cancer
13 September 2018 - Subcutaneous formulation takes two to five minutes to administer, rather than up to 90 minutes with the ...
Posted by Michael Wonder on 07 Sep 2018
Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
6 September 2018 - Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory ...
Posted by Michael Wonder on 05 Sep 2018
Health Canada approves Perjeta (pertuzumab) for the treatment of HER2 positive early breast cancer after surgery
4 September 2018 - New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning ...
Posted by Michael Wonder on 31 Jul 2018
New treatment option for Canadians with metastatic lung cancer
30 July 2018 - Takeda Canada has received Notice of Compliance with conditions approval from Health Canada for Alunbrig (brigatinib) indicated ...
Posted by Michael Wonder on 13 Jul 2018
Health Canada approves Tagrisso (osimertinib) as first-line treatment for EGFR-mutated non-small cell lung cancer
12 July 2018 - Pivotal FLAURA study demonstrated 18.9 months median progression-free survival for patients receiving Tagrisso versus 10.2 months compared ...
Posted by Michael Wonder on 10 Jul 2018
Health Canada approves Gazyva for previously untreated advanced follicular lymphoma
9 July 2018 - Gazyva is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma. ...
Posted by Michael Wonder on 09 Jul 2018
Only immuno-oncology combination therapy approved by Health Canada as first-line treatment for advanced or metastatic renal cell carcinoma
9 July 2018 - Opdivo (nivolumab) and Yervoy (ipilimumab) combination is the first and only treatment to show significantly superior ...
Posted by Michael Wonder on 05 Jul 2018
Health Canada approves Erleada (apalutamide tablets), the first treatment for men with non-metastatic castration-resistant prostate cancer
4 July 2018 - Erleada decreased the risk of metastasis or death in patients by 70% and improved median metastasis-free survival ...
Posted by Michael Wonder on 14 Jun 2018
Alecensaro (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer
13 June 2018 - Targeted oral treatment shown to reduce risk of death or disease progression by more than half compared ...
Posted by Michael Wonder on 11 May 2018
Lynparza (olaparib) receives new indication for BRCA-mutated metastatic breast cancer
10 May 2018 - Lynparza has been shown to reduce the risk of disease progression or death by 42% compared ...
Posted by Michael Wonder on 10 May 2018
First and only immuno-oncology treatment, Imfinzi (durvalumab), for stage III, unresectable non-small-cell lung cancer now approved in Canada
9 May 2018 - Patients receiving Imfinzi in the PACIFIC clinical trial lived for nearly one year without their disease ...
Posted by Michael Wonder on 09 May 2018
Lynparza (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status
8 May 2018 - The treatment demonstrates a 65% reduction in disease progression or death. ...
Posted by Michael Wonder on 02 May 2018
Health Canada approves Kisqali for the treatment of HR-positive and HER2-negative metastatic breast cancer in post-menopausal women in combination with letrozole as an initial endocrine-based therapy
2 May 2018 - Arrival of new first-line therapy provides additional option for those living with this advanced form of breast ...
Posted by Michael Wonder on 09 Apr 2018
Health Canada approves Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small-cell lung cancer
9 April 2018 - Tecentriq provides a new cancer immunotherapy option for Canadians living with the difficult disease. ...